3-氟--5-甲基苯甲醛 | 189628-39-5

• 物质功能分类: 化学试剂 - 有机试剂 - 芳烃
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氟--5-甲基苯甲醛
• 中文别名: 3-氟-5-甲基苯甲醛
• 英文名称: 3-fluoro-5-methylbenzaldehyde
• CAS: 189628-39-5
• 化学式: C₈H₇FO
• 分子量: 138.141
• InChiKey: XXPITUUQKCGWNR-UHFFFAOYSA-N

物化性质

• 沸点：
  198℃
• 密度：
  1.136
• 闪点：
  79℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2913000090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  3-氟--5-甲基苯甲醛 在 sodium tetrahydroborate 、 三溴化磷 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 5.33h， 生成 3-氟-5-甲基苄基溴化物
  参考文献：
  名称：

  Development of a Phase-Transfer-Catalyzed, [2,3]-Wittig Rearrangement

  摘要：

  An investigation into the use of phase-transfer catalysis for the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds is described. Initial studies focused on identifying viable substrate classes that would undergo selective [2,3]-rearrangement under phase-transfer catalysis. Under certain conditions, the [2,3]-sigmatropic rearrangement of allyloxy carbonyl compounds takes place in the presence of a phase-transfer agent, providing a rare example of a phase-transfer-catalyzed unimolecular reaction. In the course of this investigation, it was found that catalysis is dependent on several variables including base concentration, catalyst structure, and substrate lipophilicity. Preliminary testing of chiral, nonracemic phase-transfer catalysts has shown promising levels of enantioselectivity for future development.

  DOI：

  10.1021/acs.joc.5b01759
• 作为产物：
  描述：

  5-氟-3-碘甲苯 、 9-methyl-9H-fluorene-9-carbonyl chloride 在 dichloro(cycloocta-1,5-diene)palladium (II) 、 N-甲基二环己基胺 、 potassium formate 、 四丁基碘化铵 、 tricyclohexylphosphine tetrafluoroborate 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 乙腈 为溶剂， 反应 18.0h， 以96%的产率得到3-氟--5-甲基苯甲醛
  参考文献：
  名称：

  Reductive Carbonylation of Aryl Halides Employing a Two-Chamber Reactor: A Protocol for the Synthesis of Aryl Aldehydes Including ¹³C- and D-Isotope Labeling

  摘要：

  A protocol has been developed for conducting the palladium-catalyzed reductive carbonylation of aryl iodides and bromides using 9-methylfluorene-9-carbonyl chloride (COgen) as a source of externally delivered carbon monoxide in a sealed two-chamber system (COware), and potassium formate as the in situ hydride source. The method is tolerant to a wide number Of functional groups positioned on the aromatic ring, and it can be exploited for the isotope labeling of the aldehyde group. Hence, reductive carbonylations run with (13)COgen provide a facile access to C-13-labeled aromatic aldehydes, whereas with DCO2K, the aldehyde is specifically labeled with deuterium. Two examples of double isotopic labeling are also demonstrated. Finally, the method was applied to the specific carbon-13 labeling of the beta-amyloid binding compound, florbetaben.

  DOI：

  10.1021/jo400741t

文献信息

• THIAZOLIDINONE COMPOUNDS AND USE THEREOF
  申请人：National Health Research Institutes

  公开号：US20170253569A1

  公开（公告）日：2017-09-07

  A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

  一种含有化合物（I）的药物组合物，用于治疗与阿片受体相关的疾病。还公开了一种使用这种化合物治疗阿片受体相关疾病的方法。进一步公开了两组式（I）的噻唑烷酮化合物：（i）每种化合物的对映体过量大于90%；（ii）每种化合物被氘取代。
• INHIBITORS OF STEAROYL-COA DESATURASE
  申请人：Gillespie Paul

  公开号：US20090149466A1

  公开（公告）日：2009-06-11

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

  提供以下式(I)化合物： 以及药用可接受的盐，其中取代基如说明书中所披露。这些化合物以及包含它们的药物组合物可用于治疗诸如肥胖等疾病。
• Synthesis and structure–activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists
  作者：Gaifa Lai、J. Robert Merritt、Zhenmin He、Daming Feng、Jianhua Chao、Michael F. Czarniecki、Laura L. Rokosz、Tara M. Stauffer、Diane Rindgen、Arthur G. Taveras

  DOI：10.1016/j.bmcl.2008.02.010

  日期：2008.3

  A series of 3,4- and 3,5-disubstituted phenyl-containing cyclobutenedione analogues were synthesized and evaluated as CXCR2 receptor antagonists. Variations in the disubstitution pattern of the phenyl ring afforded new compounds with potent CXCR2 binding affinity in the low nanomolar ranges. Moreover, two potent compounds 19 and 26 exhibited good oral pharmacokinetic profiles.

  合成了一系列的3,4-和3,5-二取代的含苯基环丁烯二酮类似物，并将其评估为CXCR2受体拮抗剂。苯环解离模式的变化提供了在低纳摩尔范围内具有有效CXCR2结合亲和力的新化合物。此外，两种有效的化合物19和26表现出良好的口服药代动力学特征。
• Regio- and Stereoselective Alkenylation of Allenoates with <i>gem</i>-Difluoroalkenes: Facile Access to Fluorinated 1,4-Enynes Bearing an All-Carbon Quaternary Center
  作者：Qi-Qi Zhang、Shi-Yong Chen、E Lin、Honggen Wang、Qingjiang Li

  DOI：10.1021/acs.orglett.9b00775

  日期：2019.5.3

  A regio- and stereoselective synthesis of fluorinated 1,4-enynes bearing an all-carbon quaternary center at the propargylic position is developed. The synthesis starts from readily available allenoates and gem-difluoroalkenes and proceeds via a key alkynylenolate intermediate following a nucleophilic addition/β-F elimination. This reaction occurs under mild reaction conditions with good tolerance to

  开发了在炔丙基位置带有全碳四元中心的氟化1,4-烯炔的区域和立体选择性合成。从容易获得的联烯酸酯和合成启动宝石-difluoroalkenes并且进行经由键alkynylenolate中间以下的亲核加成/β-F的消除。该反应在对各种官能团具有良好耐受性的温和反应条件下发生。产品的进一步转化证明了合成的效用。此外，该反应还可以通过使用3，3-二取代的脲基酸酯而应用于α-烯基脲基酸酯的合成。
• Design, synthesis, and Structure–Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors
  作者：Yunxin Duan、Jie Wang、Sihua Zhu、Zheng-Chao Tu、Zhang Zhang、Shingpan Chan、Ke Ding

  DOI：10.1016/j.ejmech.2020.112552

  日期：2020.10

  by the US FDA approval of small molecular Trk inhibitors Larotrectinib (1, LOXO-101) and Entrectinib (2). However, gene mutation mediated resistance becomes a major challenge for Trk inhibitor therapies. Herein, we report the design, synthesis and Structure–Activity Relationship investigation of a series of 3-vinylindazole derivatives as new Trk inhibitors with low nanomolar potencies. A representative

  神经营养受体酪氨酸激酶（NTRK）融合是多种成年和小儿肿瘤的致癌驱动因子，已通过美国FDA批准的小分子Trk抑制剂Larotrectinib（1，LOXO-101）和ENTrectinib（2）验证。然而，基因突变介导的耐药性成为Trk抑制剂治疗的主要挑战。在本文中，我们报告了一系列3-乙烯基吲唑衍生物作为新型Trk抑制剂的设计，合成和结构-活性关系研究，该抑制剂具有低纳摩尔浓度。有代表性的化合物，7MB，结合与TrkA / B / C与ķ d 1.6，3.1和4.9纳米的值，并抑制它们的激酶功能与IC 50值分别为1.6、2.9和2.0 nM，但在KINOMEscan选择性研究中，对于大多数403种野生型激酶的大多数而言，其效价显然较低。该化合物还有效地抑制了BaF3细胞用NTRK融合与IC稳定转化的面板的增殖50在低nM范围内的值。此外，该化合物对具有NTRK1-G667C或NTRK3-G696A突变且IC